Monte Rosa Therapeutics Stock Alpha and Beta Analysis
| GLUE Stock | USD 14.40 0.91 5.94% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Monte Rosa Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Monte Rosa over a specified time horizon. Remember, high Monte Rosa's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Monte Rosa's market risk premium analysis include:
Beta 0.47 | Alpha 1.09 | Risk 5.68 | Sharpe Ratio 0.21 | Expected Return 1.18 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Monte Rosa Backtesting, Monte Rosa Valuation, Monte Rosa Correlation, Monte Rosa Hype Analysis, Monte Rosa Volatility, Monte Rosa History and analyze Monte Rosa Performance. Monte Rosa Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Monte Rosa market risk premium is the additional return an investor will receive from holding Monte Rosa long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Monte Rosa. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Monte Rosa's performance over market.| α | 1.09 | β | 0.47 |
Monte Rosa expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Monte Rosa's Buy-and-hold return. Our buy-and-hold chart shows how Monte Rosa performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Monte Rosa Market Price Analysis
Market price analysis indicators help investors to evaluate how Monte Rosa stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Monte Rosa shares will generate the highest return on investment. By understating and applying Monte Rosa stock market price indicators, traders can identify Monte Rosa position entry and exit signals to maximize returns.
| Price Series Summation | ||
| Price Series Division | ||
| Inverse Tangent Over Price Movement | ||
| Price Ceiling Movement | ||
| Aroon Oscillator | ||
| Balance Of Power | ||
| Simple Moving Average | ||
| Parabolic SAR | ||
| Stalled Pattern | ||
| Separating Lines |
Monte Rosa Return and Market Media
The median price of Monte Rosa for the period between Wed, Oct 8, 2025 and Tue, Jan 6, 2026 is 14.16 with a coefficient of variation of 23.03. The daily time series for the period is distributed with a sample standard deviation of 3.11, arithmetic mean of 13.52, and mean deviation of 2.63. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | America.Fun Launches as Special Projects Arm of Bonk in the Bonk x WLFI x Raydium Partnership | 10/09/2025 |
2 | Visual trend scoring systems applied to Monte Rosa Therapeutics Inc. - Watch List Daily Chart Pattern Signals - newser.com | 11/05/2025 |
3 | Los Angeles Capital Management LLC Takes Position in Monte Rosa Therapeutics, Inc. GLUE | 11/19/2025 |
4 | Monte Rosa Therapeutics Hits New 12-Month High - Should You Buy - MarketBeat | 11/25/2025 |
5 | How Monte Rosa Therapeutics Inc. stock reacts to inflationary pressures - Quarterly Earnings Summary Real-Time Buy Signal Notifications - B NI V | 11/28/2025 |
6 | Monte Rosa Therapeutics, Inc. Stock Catapults 28 percent Though Its Price And Business Still Lag The Industry | 12/03/2025 |
7 | Disposition of 75011 shares by Sharon Townson of Monte Rosa at 1.13 subject to Rule 16b-3 | 12/05/2025 |
8 | Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 12 Study Results | 12/15/2025 |
9 | Assessing Monte Rosa Therapeutics After Its 162.4 percent Surge and DCF Implied Upside in 2025 - Yahoo Finance | 12/17/2025 |
10 | Monte Rosa Therapeutics price target increased by 22.54 percent to 21.78 - MSN | 12/24/2025 |
11 | Acquisition by Sharon Townson of 35000 shares of Monte Rosa subject to Rule 16b-3 | 01/02/2026 |
12 | Disposition of 3155 shares by Sharon Townson of Monte Rosa at 15.17 subject to Rule 16b-3 | 01/05/2026 |
About Monte Rosa Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Monte or other stocks. Alpha measures the amount that position in Monte Rosa Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2025 | 2026 (projected) | Interest Debt Per Share | 0.52 | 0.66 | Revenue Per Share | 0.92 | 0.82 |
Monte Rosa Upcoming Company Events
As portrayed in its financial statements, the presentation of Monte Rosa's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Monte Rosa's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Monte Rosa's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Monte Rosa. Please utilize our Beneish M Score to check the likelihood of Monte Rosa's management manipulating its earnings.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Monte Rosa
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Monte Rosa Backtesting, Monte Rosa Valuation, Monte Rosa Correlation, Monte Rosa Hype Analysis, Monte Rosa Volatility, Monte Rosa History and analyze Monte Rosa Performance. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Monte Rosa technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.